8 results about "Anserine" patented technology

The invention provides a method for extracting goose carnosine and / or carnosine. The method comprises the steps of low-salt water extraction and high-salt water extraction under alkaline and heating conditions. The extraction method of the goose carnosine and / or carnosine provided by the invention is simple to operate, low in cost and easy for large-scale industrial use.

The application discloses a tetrapeptide IR4 with uric acid reducing activity, and a preparation method and application thereof, and belongs to the technical field of small molecular peptides. The amino acid sequence of the tetrapeptide IR4 is IDWR, and the tetrapeptide IR4 can be prepared by a solid-phase synthesis method and an enzymatic hydrolysis method. The tetrapeptide IR4 is identified from a porphyra haitanensis protease hydrolysate, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebrafish by 33.6% (to 5.93+ / -0.47 mu mol / g protein) at a concentration of 100 mu g / mL. Compared with an anserine (which can reduce the uric acid content of zebrafish by 25.7%), the tetrapeptide IR4 has better uric acid reducing activity. Compared with allopurinol (which can reduce the uric acid content of zebrafish to 4.61+ / -1.11 mu mol / g protein), the uric acid reducing ability of the tetrapeptide IR4 and the allopurinol has no significant difference. The tetrapeptide IR4 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

An imidazole dipeptide composition having renal protective efficacy and its application. The imidazole dipeptide composition having renal protective efficacy comprises anserine and carnosine, wherein, when the total weight of anserine and carnosine is 100%, the content of anserine is 10% to 99% and the content of carnosine is 1% to 90%. In a mouse test, mice with hyperuric kidney damage showed significantly less kidney damage compared to the control group after continuously consuming the imidazole dipeptide composition for a certain period, and the imidazole dipeptide composition was proven to have an excellent renal protective effect.

The present application relates to the technical field of food and beverage processing, and discloses a milk tea based on synergistic buffering of goose dipeptide and dipeptide and a preparation method thereof.The milk tea contains, by weight percentage, 0.15%-0.45% of a core dipeptide compound, 5.0%-10.0% of a plant or A2 milk powder matrix, 0.02%-0.08% of a neuromodulator, 0.05%-0.15% of a metabolic auxiliary factor, and sweeteners, flavor modifiers and pH buffers.The mass ratio of goose dipeptide to dipeptide in the core dipeptide compound is 3:1-4:1, and the dipeptide is double-modified by beta-cyclodextrin embedding and tea polyphenol complexing to mask the astringent taste of the dipeptide.The preparation process adopts tea-milk base high-temperature sterilization, active liquid cross-flow membrane cold filtration sterilization, separate cavity dosing and aseptic cold filling technology to block the Maillard reaction of heat-sensitive peptides.The present application can target intervention in the increase of uric acid, lactic acid accumulation and tissue glycation caused by night work, and relieve physiological metabolic abnormalities.

The application discloses a pentapeptide LE5 with xanthine oxidase inhibiting activity and a preparation method and application thereof, and belongs to the technical field of small-molecule peptides. The amino acid sequence of the pentapeptide LE5 is LGGVE, and the pentapeptide LE5 can be prepared by a solid-phase synthesis method and an enzymolysis method. The pentapeptide LE5 is identified from a Gracilaria lemaneiformis protein enzymolysis liquid, has potential interaction with xanthine oxidase, and has an xanthine oxidase inhibition rate of 60.58% at a concentration of 0.1 mg / mL. Compared with an anserine (xanthine oxidase inhibition rate of 36.03%), the xanthine oxidase inhibition rate is extremely significantly increased (p<0.001), and the xanthine oxidase inhibiting activity is stronger, so that the pentapeptide LE5 can be used for preparing an xanthine oxidase activity inhibiting preparation and relieving hyperuricemia.

The invention discloses a pentapeptide LE5 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the pentapeptide LE5 is LGGVE, and the pentapeptide LE5 can be prepared through a solid-phase synthesis method and an enzymolysis method. The pentapeptide LE5 is identified from eucheuma proteolysis liquid and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 60.58%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; and the compound has higher xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The invention discloses tetrapeptide IR4 with uric acid reducing activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptide. The amino acid sequence of the tetrapeptide IR4 is IDWR, and the tetrapeptide IR4 can be prepared through a solid-phase synthesis method and an enzymolysis method. The tetrapeptide IR4 is identified from porphyra haitanensis proteolysis liquid, has potential interaction with xanthine oxidase, can reduce the uric acid content of zebra fish by 33.6% (reduced to 5.93 + / -0.47 [mu] mol / g protein) when the concentration is 100 [mu] g / mL, and has better uric acid reducing activity compared with goose carnosine (which can reduce the uric acid content of zebra fish by 25.7%). Compared with allopurinol (the uric acid content of zebra fish can be reduced to 4.61 + / -1.11 mu mol / g protein), the tetrapeptide IR4 and allopurinol have no significant difference in uric acid reducing capacity, and the tetrapeptide IR4 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

This invention belongs to the fields of traditional Chinese medicine and biomedicine, specifically relating to compositions that promote lactation, their preparation methods, and applications. First, this invention establishes an animal model of lactation deficiency to evaluate the efficacy of traditional Chinese medicine, natural products, and their combinations in promoting lactation. Using this model, a large number of naturally derived active ingredients were screened, yielding highly effective active ingredients such as astragaloside A, codonopsis glycoside, ferulic acid, lycine spermidine, carnosine, and anserine. These active ingredients were then combined to prepare compositions. Based on this, traditional Chinese medicine compositions and food-medicine homologous traditional Chinese medicine compositions with the aforementioned active ingredients as their core were also prepared. This invention evaluated the three compositions using the lactation deficiency animal model, finding that all three compositions significantly promoted lactation. Therefore, this invention has significant clinical value and broad market application prospects, and can meet the needs of people requiring lactation.